ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements
Anthem delivered robust Q2 results driven by CRDMO business and sharp margin expansion. Management highlighted strong operating leverage and cost discipline while scaling capacity.
Q2FY27 revenue ₹5,940 Mn (+7.9% YoY), PAT ₹2,115 Mn (+21.9%), EBITDA margin 50.6% including ₹589 Mn other income. H1FY27 revenue fell 7.2%.
Anthem Biosciences reported Q2 FY27 consolidated revenue of ₹5,940 Mn, up 7.9% year-on-year, and PAT of ₹2,115 Mn. H1 FY27 PAT rose 7.2% to ₹3,314 Mn.
Anthem Biosciences Ltd reported revenue from operations of ₹594 Cr (+7.9% YoY) and net profit of ₹211.5 Cr (+22.0% YoY) for Q2 FY27.
Anthem Biosciences scheduled a Board meeting for November 3, 2026 to approve Q1 and H1 FY27 financial results. The trading window remains closed until November 5, 2026.
Anthem Biosciences Ltd has submitted its quarterly shareholding pattern as per SEBI regulations. The filing provides the current distribution of promoter and public shareholdings.
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
Anthem Biosciences appointed S.R. Batliboi & Associates LLP as Statutory Auditor and noted director changes, including a rotation and continuation of directorship.
Anthem Biosciences held its 20th AGM on July 22, 2026. Shareholders approved all business resolutions, including financial statements, dividend declaration, and statutory auditor appointments.
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Crore and profit after tax of ₹119.9 Crore. The company continues its focus on margin improvement and cost efficiencies.
Anthem reported Q1FY27 revenue of ₹4,182 Mn with a 39.6% EBITDA margin. Results reflect timing shifts in deliveries, though management reports strong underlying demand and year-on-year margin improvement.
Anthem Biosciences Ltd reported revenue from operations of ₹418.2 Cr (-22.6% YoY) and net profit of ₹119.9 Cr (-11.7% YoY) for Q1 FY27.
Anthem Biosciences scheduled a board meeting on July 21, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Anthem Biosciences sent shareholders a letter with a web link and exact path to access its FY 2025‑26 annual report. The notice meets SEBI Regulation 36(1)(b).
Anthem Biosciences Ltd received an ICRA rating upgrade to AA (Stable) for its facilities totaling Rs.275.5 Crore. Revised ratings cover working capital, term loan, short‑term and unallocated limits.
Anthem Biosciences clarified minor discrepancies in its FY25-26 financial results. It will file a revised XBRL to include the omitted consolidated EPS.
Anthem Biosciences submitted its Business Responsibility and Sustainability Report for FY 2025-26. The filing details the company's operational sustainability and governance disclosures.
Anthem Biosciences Limited filed its Annual Report for FY 2025-26. The report includes key highlights and operational journeys.
Anthem Biosciences scheduled its 20th Annual General Meeting for July 22, 2026. The meeting will be conducted via video conferencing.
Anthem Biosciences scheduled a facility visit for institutional investors in Bangalore on June 10, 2026. The meeting will be led by CFO Mohammed Gawir Baig.
Anthem Biosciences delivered record Q4 performance with FY26 revenue of ₹2,280cr and 43.4% EBITDA margins, driven by CRDMO strength.
Anthem Biosciences allotted 1,481,250 equity shares under its ESOP scheme. This issuance increased the company's total paid-up share capital to 563,195,101 shares.
Anthem Biosciences recommended a final dividend of INR 2 per share for FY 2025-26. The record date is June 26, 2026, with payment by August 21.
Anthem delivered robust FY26 growth, overcoming destocking challenges in their core CRDMO segment.
Anthem Biosciences board approved re-appointing Whole Time Director K Ravindra Chandrappa. Independent Director Ravikant Uppal continues beyond age 75, ensuring leadership continuity.
Anthem Biosciences Limited disclosed its certified Key Performance Indicators for the financial year ended March 31, 2026. The metrics provide detailed historical operational visibility for investors.
Anthem Biosciences reported FY26 consolidated revenue of ₹2124.3 Crore with a 26% PAT margin. Strong quarterly performance was driven by 30.7% YoY growth in CRDMO segment.
Anthem Biosciences achieved record Q4FY26 revenue of ₹6,109 Mn. The company delivered 15.2% FY26 revenue growth with strong EBITDA margins of 43.4% driven by its CRDMO segment.